Eculizumab treatment alters the proteometabolome beyond the inhibition of complement

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement

Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis (MG). However, a deeper understanding of complement modulation in the human system is required to improve treatment responses and identify off-target effects shaping long-term outcomes. For this reason...

Full description

Bibliographic Details
Main Authors: Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, Niklas Huntemann, Marc Pawlitzki, Alice Willison, Saskia Räuber, Nico Melzer, Ute Distler, Stefan Tenzer, Kai Stühler, Andreas Roos, Andreas Meisel, Sven G. Meuth, Tobias Ruck
Format: Article
Language:English
Published: American Society for Clinical investigation 2023-07-01
Series:JCI Insight
Subjects:
Autoimmunity
Neuroscience
Online Access:https://doi.org/10.1172/jci.insight.169135

Internet

https://doi.org/10.1172/jci.insight.169135

Similar Items